Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

Novel Repositionable TAVR Device Sees Low Pacemaker Rates and Few Leaks

Shelley Wood

December 19, 2017

News Daily News

Isolated Tricuspid Valve Surgery Remains Rare and Risky

Caitlin E. Cox

December 13, 2017

News Daily News

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Caitlin E. Cox

November 30, 2017

News Conference News AHA 2017

TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery

Shelley Wood

November 12, 2017

News Conference News TCT 2017

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

Ashley Lyles

November 08, 2017

News Conference News TCT 2017

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Yael L. Maxwell

November 02, 2017

Presentation TCT 2017

TCT 34: Prediction of Acute Kidney Injury After TAVR by New Biomarkers

Presenter: Reginald I. Low, Michael J. Rinaldi, Mani Arsalan, MD

October 31, 2017

News Daily News

Some Reassurances, Some Sobering Truths About Dialysis Needs After TAVR

Shelley Wood

October 16, 2017

News Daily News

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

Shelley Wood

October 10, 2017

News Daily News

After Failed Mitral Valve Surgery, Transcatheter Valve-in-Valve or Valve-in-Ring Shows Promise in High-Risk Patients

Yael L. Maxwell

August 24, 2017

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

News Industry News

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

May 15, 2017

News Daily News

Cardiac Intensive Care Units Face an Ever More Complex Patient Population

Caitlin E. Cox

April 28, 2017

News Conference News ACC 2017

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Shelley Wood

March 24, 2017

News Conference News ACC 2017

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

Todd Neale

March 19, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Advertisement

Novel Repositionable TAVR Device Sees Low Pacemaker Rates and Few Leaks

Isolated Tricuspid Valve Surgery Remains Rare and Risky

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

TRICS III: Restrictive Red-Cell Transfusion Noninferior to Liberal Use in Cardiac Surgery

TAVR Beats Out SAVR, at Least In-Hospital, for Patients With Prior CABG

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

TCT 34: Prediction of Acute Kidney Injury After TAVR by New Biomarkers

Some Reassurances, Some Sobering Truths About Dialysis Needs After TAVR

Excluded From Trials, Patients With Severe Kidney Disease Benefit Less From TAVR

After Failed Mitral Valve Surgery, Transcatheter Valve-in-Valve or Valve-in-Ring Shows Promise in High-Risk Patients

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year

Cardiac Intensive Care Units Face an Ever More Complex Patient Population

TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes

Cerebral Embolic Protection During Surgical AVR Fails to Show a Benefit

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content